Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma

Open access
Albiges, Laurence, Oudard, Stéphane, Negrier, Sylvie, Caty, Armelle, Gravis, Gwenaëlle, Joly, Florence, Duclos, Brigitte, Geoffrois, Lionel, Rolland, Frédéric, Guillot, Aline, Laguerre, Brigitte, Legouffe, Eric, Kohser, Frédéric, Dietrich, Pierre-Yves, Theodore, Christine A., Escudier, Bernard · 2012 · Journal of Clinical Oncology

Abstract

Purpose: Complete remission (CR) is uncommon during treatment for metastatic renal cell carcinoma (mRCC) with tyrosine kinase inhibitors (TKIs), but it may occur in some patients. It remains a matter of debate whether therapy should be continued after CR. Methods: A multicenter, retrospective analysis of a series of patients with mRCC who obtained CR during treatment with TKIs (sunitinib or sorafenib), either alone or with local treatment (surgery, radiotherapy, or radiofrequency ablation), was performed. Results: CR was identified in 64 patients; 36 patients had received TKI treatment alone and 28 had also received local treatment. Most patients had clear cell histology (60 of 64 patients), and all had undergone previous nephrectomy. The majority of patients were favorable or intermediate risk; however, three patients were poor risk. Most patients developed CR during sunitinib treatment (59 of 64 patients). Among the 36 patients who achieved CR with TKI alone, eight continued TKI treatment after CR, whereas 28 stopped treatment. Seventeen patients who stopped treatment (61%) are still in CR, with a median follow-up of 255 days. Among the 28 patients in CR after TKI plus local treatment, 25 patients stopped treatment, and 12 of these patients (48%) are still in CR, with a median follow-up of 322 days. Conclusion: CR can occur after TKI treatment alone or when combined with local treatment. CR was observed at every metastatic site and in every prognostic group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.37.2516

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 163

Metadata

Authors
Albiges, L., Oudard, S., Negrier, S., Caty, A., Gravis, G., Joly, F., Duclos, B., Geoffrois, L., Rolland, F., Guillot, A., Laguerre, B., Legouffe, E., Kohser, F., Dietrich, P.-Y., Theodore, C. A., & Escudier, B.
Venue
Journal of Clinical Oncology
Published
2012-02-10
Volume
30
Issue
5
Pages
482-487
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2117547860
Cited by
163
References
1
FWCI
17.55
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1200/jco.2011.37.2516
The paper
Albiges, L., Oudard, S., Negrier, S., Caty, A., Gravis, G., Joly, F., Duclos, B., Geoffrois, L., Rolland, F., Guillot, A., Laguerre, B., Legouffe, E., Kohser, F., Dietrich, P.-Y., Theodore, C. A., & Escudier, B. (2012). Complete Remission With Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.37.2516

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.